isavuconazole has been researched along with Lassa-Fever* in 1 studies
1 other study(ies) available for isavuconazole and Lassa-Fever
| Article | Year |
|---|---|
The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein.
Lassa virus (LASV) is the causative agent of Lassa hemorrhagic fever in humans, and the limited therapeutic treatment for Lassa fever poses significant threat to public health in West Africa. Using an HIV based pseudovirus platform, we identified isavuconazole, a triazole antifungal for systemic use, as a LASV entry inhibitor with an EC Topics: A549 Cells; Antifungal Agents; Antiviral Agents; Cell Line; Drug Repositioning; Glycoproteins; HEK293 Cells; Humans; Lassa Fever; Lassa virus; Nitriles; Protein Sorting Signals; Pyridines; Triazoles; Viral Envelope Proteins; Viral Proteins; Virus Internalization | 2020 |